Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in advanced gastric cancer (GRANITE-1)
NCT00879333Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma comparing Everolimus + BSC with Placebo + BSC (2 arms). Primary endpoint: Overall Survival at 2.5 years. Started Jul 2009; status: completed.
02
Drugs
everolimus
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT00879333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00879333.